24СʱÈÈÃŰæ¿éÅÅÐаñ    

²é¿´: 1244  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

ÒøÉþ

ľ³æ (ÖøÃûдÊÖ)

Ö²Îï²ËÄñ

[ÇóÖú] ¹ØÓÚRRAFµÄÓ¢ÎÄ·­Ò룬ÓÐЩ¼±£¬Âé·³°ïæ½âÊÍÏ£¬·Ç³£¸Ðл£¡

1.BRAF inhibitors drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling in oncogenic RAS revealing a paradigm of BRAF-mediated signaling that promotes tumour progression with clinical implications and highlighting the importance of understanding pathway signaling in clinical practice and of genotyping tumours prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects such as increased invasion¡£
ÕâÊÇÍêÕûµÄÒ»¾ä»°£¬ÓÐЩ³¤£¬Ö÷ÒªÏëÖªµÀRAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling £¬a paradigm of BRAF-mediated signalingÊÇʲôÒâ˼
2.panRAF inhibitors with anti SRC activity

» ²ÂÄãϲ»¶

°®ºÃÖ²Îµ«ÊÇÊÇÒ»Ö»²ËÄñ£¡
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÒøÉþ

ľ³æ (ÖøÃûдÊÖ)

Ö²Îï²ËÄñ

Çó´óÉñ°ïæ

[ ·¢×ÔСľ³æ¿Í»§¶Ë ]
°®ºÃÖ²Îµ«ÊÇÊÇÒ»Ö»²ËÄñ£¡
2Â¥2015-05-09 22:59:41
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

genhunter

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

BRAF inhibitors drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling in oncogenic RAS revealing a paradigm of BRAF-mediated signaling that promotes tumour progression with clinical implications and highlighting the importance of understanding pathway signaling in clinical practice and of genotyping tumours prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects such as increased invasion¡£
BRAF ÒÖÖÆ¼Á´ÙʹRAS-ÒÀÀµµÄBRAF½áºÏµ½CRAF, CRAFµÄ»î»¯£¬ÒÔ¼°Ö°© RASÐźŴ«µÝͨµÀÖеÄMEK-ERKÐźŴ«µÝ×÷ÓýÒʾÁËÒ»¸öÓÉ BRAF-½éµ¼µÄ£¬¸´ÔÓµÄÐźŴ«µÝ;¾¶£¬ÔÚ¾ßÓÐÁÙ´²Ñ§ÒâÒåµÄ´Ù½øÖ×Áö¶ñ»¯½ø³Ì(µÄ×÷ÓÃ), Í»³öÁËÁ˽â¸ÃÐźŴ«µÝ;¾¶ÔÚÁÙ´²Ó¦ÓÃÉϺÍÔÚʹÓÃBRFA-Ñ¡ÔñÐÔÒ©Îï֮ǰ¶ÔÖ×Áö×÷»ùÒò·ÖÀàµÄÖØÒªÐÔ£¬ÒÔ¼°¼ø±ðÄÄЩ»¼Õß¿ÉÄܶԴËÀàÒ©ÎïÓÐЧ£¬¶øÄÄЩ»á³öÏÖÔö¼ÓÀýÈçÖ×Áö×ªÒÆµÄ²»Á¼·´Ó¦¡£
Àë³É¹¦»¹²îÒ»µã
3Â¥2015-05-09 23:20:27
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ssssllllnnnn

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)

Translator and Proofreader


¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
ÒøÉþ: ½ð±Ò+10, ·­ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл´óÉñµÄÄÍÐĽâ´ð£¬°ïÖúºÜ´ó 2015-05-10 12:40:36
ÍêÈ«Àí½âÕâ¾ä»°ÐèÒªÁ˽âRAS¡¢BRAF¡¢CRAFÒÔ¼°MEK-ERKÕâЩ»ù±¾µÄ¶«Î÷¼°ÆäÒâÒå¡£ÏÔÈ»Õâ²»ÊÇÒ»Á½¾ä»°¾ÍÄÜ˵µÄÇå³þµÄ¡£¼òµ¥Ëµ£º
1¡¢RasÊÇÒ»ÖÖ°©»ùÒò£¨oncogene£©£¬Æä±àÂë²úÎïÒÔÒ»ÖÖСGTPø£¨small GTPase£©£¬²ÎÓëÖØÒªµÄÐźŴ«µ¼¹ý³Ì£¨°üÀ¨ÄãµÄÄÚÈÝ£©£¬RasÊÇÒ»¸ö¼Ò×壬Óжà¸ö³ÉÓ°üÀ¨K-ras, H-ras, N-rasµÈ£»
2¡¢RAFÊÇÒ»ÀàË¿°±Ëá/ËÕ°±ËáÌØÒìÐÔµ°°×¼¤Ã¸£¨serine/threonine-specific protein kinases£©£¬¼ò³ÆÎªRaf¼¤Ã¸£¨Raf kinase£©£¬ÓÉÈý¸ö³ÉÔ±£¬·Ö±ðΪA-RAF, B-RAFºÍC-RAF£¬ÆäÖÐC-RAFÒ²³ÆÎªRaf-1£¬ÄãµÄÄÚÈÝÖÐÖ÷񻃾¼°AºÍC-RAF¡£¶ÔÁË£¬Ëùν¼¤Ã¸¾ÍÊÇ¿ÉÒÔÒýÆðµ°°×ÖÊÁ×ËữµÄøÀà¡£
3¡¢RAS£¬RAFºÍºóÃæÌáµ½µÄMEF-ERK¹²Í¬¹¹³ÉÁËÒ»Ìõ·Ç³£ÖØÒªµÄÐźÅͨ·£¬Í¨³£³ÆÖ®ÎªRAS-RAF-MEK-ERKÐźÅͨ·£¨RAS-RAF-MEK-ERK signal pathway£© Ò²½ÐË¿ÁÑÔ­¼¤»îµ°°×¼¤Ã¸£¨MAPK£©Í¨Â·£¨mitogen-activated protein kinase (MAPK) cascade£©, ÆäÖÐRAF¼¤Ã¸µÄ»î»¯¾ÍÐèÒªÓëRAS-GTPases£¨GTPø£©Ï໥×÷Óã¬ÕâÒ²¾ÍÊÇÎÄÖÐËùÌá¼°µÄ¡±RAS-dependent BRAF binding to CRAFÒÔ¼°CRAF activation¡°µÄ¹ý³ÌºÍº¬Òå¡£ MEK-ERKÏÔÈ»ÊÇÕû¸öÐźÅͨ·µÄÒ»²¿·Ö£¬Õû¸öÐźÅͨ·¼¤»îºó£¬¾Í»áÓ°ÏìÏÂÓΰлùÒòµÄ±í´ï£¬½ø¶ø¸Ä±äϸ°ûµÄ±íÐÍ¡£
4¡¢a paradigm of BRAF-mediated signaling˵µÄÊÇÓÐBRAF½éµ¼ µÄÐźÅͨ·µÄÒ»¸öģʽ»òÕßÀý×Ó¡£ÒòΪBRAFÔÚÕû¸öͨ·Öд¦ÓÚÉÏÓΣ¬ËùÒÔÀàËÆÒ»¸ö¿ª¹Ø×÷Óã¬ËùÒÔ³ÆÖ®ÎªÓÉBRAF½éµ¼µÄͨ·¡£
5.panRAF inhibitors with anti SRC activity£ºÊǽ²µ½RAFµÄÒÖÖÆ¼Á£¬ÕâÀïµÄÒÖÖÆ¼ÁΪpanRAF£¬panÊÇÖ¸·º»òÕßÈ«µÄÒâ˼£¬¾ÍÊÇ˵ÕâÀàÒÖÖÆ¼Á¿ÉÒÔÒÖÖÆËùÓÐÈýÖÖÀàÐ͵ÄRAF£¬¶ø·ÇÕë¶ÔÆäÖеÄijһÖÖ£»¶øÇÒ¿ÉÒÔÒÖÖÆ£¨¿¹£©SRC»îÐÔ¡£ÕâÀïÓÖÓÐÒ»¸öÃû´ÊSRC£¬ËüÒ²ÊÇÒ»ÖÖ°©»ùÒò£¬Æä²úÎïΪһÖÖÀÒ°±Ëáµ°°×¼¤Ã¸£¨tyrosine-protein kinase£©¡£Í¨¹ýʹÓÃÒÖÖÆ¼Á£¬¿ÉÒÔÓÐЧµØ×èÖ¹¡¢ÇжÏÕûÌõÐźÅͨ·£¬´Ó¶ø¿ÉÒԴﵽijÖÖÄ¿µÄ£¨°üÀ¨ÖÎÁÆ£©¡£

¼øÓÚÄãµÄÇé¿ö£¬ÎÒ¾õµÃÄã¿ÉÒÔÑ¡¶ÁµãÖÐÎĵÄÏà¹Ø×ÛÊö£¬¶ÔÆäÖи÷³ÉÔ±µÄ»ù±¾Çé¿öÓиö´óÖÂÁ˽⣬ÔÙÈ¥¶ÁÔ­ÎÄ¿ÉÄÜ»áºÃЩ¡£·ñÔòÖ»ÄÜÔÆÀïÎíÀïµÄ£¬Ð§¹û²»ºÃ¡£

˳±ã¸½ÉÏÒ»ÕÅÏà¹ØµÄͼ£¬°ïÄãÀí½â¡£
¹ØÓÚRRAFµÄÓ¢ÎÄ·­Ò룬ÓÐЩ¼±£¬Âé·³°ïæ½âÊÍÏ£¬·Ç³£¸Ðл£¡
p_40957.jpg

4Â¥2015-05-10 08:58:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ÒøÉþ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁÏѧ˶318Çóµ÷¼Á +4 February_Feb 2026-03-19 4/200 2026-03-19 23:29 by fmesaito
[¿¼ÑÐ] 294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶ +14 ݤÎÉ­ÁÖ 2026-03-18 14/700 2026-03-19 22:38 by ѧԱ8dgXkO
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©Àí¹¤´óѧ085701×ÊÔ´Óë»·¾³302·ÖÇóµ÷¼Á +3 ¿ûè÷ÎÀ¶Ó 2026-03-18 5/250 2026-03-19 19:35 by ¸øÄãÄã×¢ÒâÐÝÏ¢
[¿¼ÑÐ] 324·Ö 085600²ÄÁÏ»¯¹¤Çóµ÷¼Á +3 llllkkkhh 2026-03-18 3/150 2026-03-19 14:22 by houyaoxu
[¿¼ÑÐ] Çóµ÷¼Á +3 Mqqqqqq 2026-03-19 3/150 2026-03-19 14:11 by peike
[¿¼ÑÐ] Ò»Ö¾Ô¸ Î÷±±´óѧ £¬070300»¯Ñ§Ñ§Ë¶£¬×Ü·Ö287£¬Ë«·ÇÒ»±¾£¬Çóµ÷¼Á¡£ +3 ³¿»èÏßÓëÐǺ£ 2026-03-19 3/150 2026-03-19 13:36 by houyaoxu
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +6 Ð÷ÐÒÓë×Ó 2026-03-17 6/300 2026-03-19 13:27 by houyaoxu
[¿¼ÑÐ] ²ÄÁÏר˶ӢһÊý¶þ306 +5 z1z2z3879 2026-03-18 5/250 2026-03-19 07:43 by BruceLiu320
[¿¼ÑÐ] 330Çóµ÷¼Á +3 С²Ä»¯±¾¿Æ 2026-03-18 3/150 2026-03-18 21:55 by ÎÞи¿É»÷111
[¿¼ÑÐ] ÉúÎïѧ071000 329·ÖÇóµ÷¼Á +3 ÎÒ°®ÉúÎïÉúÎﰮΠ2026-03-17 3/150 2026-03-18 10:12 by macy2011
[¿¼ÑÐ] ¿¼ÑÐÇóµ÷¼Á +3 éÙËÌ. 2026-03-17 4/200 2026-03-17 21:43 by ÓÐÖ»ÀêÅ«
[¿¼ÑÐ] 277µ÷¼Á +5 ×ÔÓɼå±ý¹û×Ó 2026-03-16 6/300 2026-03-17 19:26 by Àîleezz
[¿¼ÑÐ] ²ÄÁÏר˶326Çóµ÷¼Á +6 Ä«ìÏæ¦Ý· 2026-03-15 7/350 2026-03-17 17:10 by ruiyingmiao
[¿¼ÑÐ] ²ÄÁϹ¤³Ìר˶274Ò»Ö¾Ô¸211Çóµ÷¼Á +6 Ñ¦ÔÆÅô 2026-03-15 6/300 2026-03-17 11:05 by ѧԱh26Tkc
[¿¼ÑÐ] 278Çóµ÷¼Á +3 Yy7400 2026-03-13 3/150 2026-03-17 08:24 by laoshidan
[¿¼ÑÐ] 0854¿ØÖƹ¤³Ì 359Çóµ÷¼Á ¿É¿çרҵ +3 626776879 2026-03-14 9/450 2026-03-16 17:42 by 626776879
[¿¼ÑÐ] 304Çóµ÷¼Á +3 ÂüÊâ2266 2026-03-14 3/150 2026-03-16 16:39 by houyaoxu
[¿¼ÑÐ] 0703Ò»Ö¾Ô¸211 285·ÖÇóµ÷¼Á +5 ly3471z 2026-03-13 5/250 2026-03-16 16:16 by ŶŶ123
[¿¼ÑÐ] 070300»¯Ñ§Ñ§Ë¶Çóµ÷¼Á +6 Ì«Ïë½ø²½ÁË0608 2026-03-16 6/300 2026-03-16 16:13 by kykm678
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á 290·ÖÓпÆÑо­Àú£¬ÂÛÎÄÔÚͶ +7 ÄåÄågk 2026-03-14 7/350 2026-03-16 10:12 by houyaoxu
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û